Today is #RareDiseaseDay, a day dedicated to raising awareness for patients impacted by rare diseases. Rare diseases contribute a meaningful disease burden, and at HI-Bio, we are developing targeted therapies for rare, immune-mediated diseases to provide patients in need with better treatments. We are committed to the development of our lead clinical candidate, felzartamab, to explore the potential of a cell depletion approach in indications including antibody mediated rejection, IgA nephropathy, lupus nephritis, and primary membranous nephropathy.
HI-Bio: A Biogen Company’s Post
More Relevant Posts
-
The management of autoimmune diseases has improved significantly since the beginning of the 21st century. However, treatment is still typically considered to be life-long and aimed at suppressing the symptoms. In this article published in NEJM, Müller et al. present a study of 15 patients with systemic lupus erythematosus (SLE) who were treated with a single infusion of CD19-targeted chimeric antigen receptor (CAR) T cells as B cell depletion is a potential strategy for achieving long-term drug-free remission. Patients received a single CAR T-cell infusion following fludarabine and cyclophosphamide preconditioning. Remarkably, all participants showed significant improvement according to disease-specific remission criteria, and immunosuppressive therapies were entirely discontinued. Although most experienced mild cytokine release syndrome, the therapy demonstrated a promising safety and efficacy profile, suggesting a new avenue for sustained remission in autoimmune diseases. https://lnkd.in/enuSFUpP #immunotherapy #autoimmunedisease #cartcelltherapy
-
-
News in advancements in IBD Care! A recent study emphasizes the importance of testing for fecal Calprotectin to identify levels of gut inflammation levels and predict long-term disease outcomes. Calpro Products Highlighted: This study relied on the Calpro Easy Extract and CalproLab ELISA to extract and analyze stool samples for fecal calprotectin (fCal). This accurate assessment aids in understanding inflammatory activity within the gut. This study highlights the potential of fCal and fecal myeloperoxidase (fMPO) as complementary tools for assessing disease during regular clinical care. By utilizing a combination of fecal biomarkers (e.g. fCal), CRP, and clinical disease activity, it is possible to identify individuals who are at risk of developing IBD complications. Read the full article https://hubs.ly/Q02pXT5S0 #IBD #MedicalResearch #PatientCare #CalproELISA #answersinlifescience #Crohns #Ulcerativecolitis
-
-
According to the American Lung Association, more than 1 million people are hospitalized each year due to pneumonia, and over 50,000 deaths are caused by this disease. The disease is the single biggest reason for morbidity and mortality in adults. So today on World Pneumonia Day let's spread awareness about the lethal nature of pneumonia. Read our latest blog to learn the role of Pneumonia Therapeutics in eradicating pneumonia, click @ https://lnkd.in/d8K4StQk #GVR #marketresearch #pneumonia #WorldPneumoniaDay #PneumoniaDay #PneumoniaTherapeutics #marketstudy #marketanalysis
-
-
"Specialist Medical Oncology in Burjeel medical city Abu Dhabi, Doh& DHA &MOH Licence 🇦🇪🇸🇾, ESMO Member, and Collaborator Extraordinaire - Let's Connect on Telegram and DM for Inspiring Partnerships!"
🔥Antiviral Therapy Utilization & 10-yr Outcomes in Resected HBV & HCV-HCC #livercancer #hcc 👉1,906 pts, 🗺️ RWD 👉Use of anti-HBV & -HCV 💊only 57 & 35% 👉early (!) anti-viral 💊 reduces mortality 🧐Impact on HCC & progression of liver disease.. the link in the comment
-
-
🤗 📝 We are happy to share this article from a group of French autoinflammatory experts, including representatives of the Tenon Hospital (RITA member since 2022). It describes the first dominant somatic mutation of MEFV p.Thr577Ala, responsible for a pyrin-associated autoinflammatory disease. Have a read! ⬇
-
Such an important topic and a must read…
Did you know that March is #AutoimmuneAwarenessMonth? What are autoimmune diseases? - #AutoimmuneDiseases occur when the body's immune system attacks healthy cells, tissues and organs. While some are common, like multiple sclerosis, many are rare. In November last year, we published our Rare and chronic autoimmune diseases special edition, sponsored by Horizon Therapeutics. In its pages, we heard from people who suffered from symptoms for decades before getting the answers they desperately needed. Read the edition for FREE at https://bit.ly/40p5wQy
-
Innovative Treatment for IgG4-Related Disease 🎯 Exciting news for those affected by IgG4-related disease, a complex immune-mediated disorder! Recent findings highlight the promise of Inebilizumab, a novel therapeutic approach that targets CD19+ B cells. 📈 A groundbreaking phase 3 trial shows Inebilizumab's potential in significantly reducing disease flares compared to placebo. The study reveals that only 10% of patients on Inebilizumab experienced flares, a stark contrast to 60% in the placebo group. Furthermore, more patients achieved flare-free remissions, both treatment-free and glucocorticoid-free. 🌟 This trial underscores the potential of CD19-targeted B-cell depletion as a game-changer in managing this challenging disease. A beacon of hope for patients striving for remission and improved quality of life! 🙌 Read Research 👉🏻 https://lnkd.in/dk2UkEsF #research #pubmed
-
Autoantibodies to peptidylarginine deiminase 4 (#PAD4) have been associated with #erosive disease in established #rheumatoid #arthritis (#RA). A recent study compared the clinical and prognostic value of anti-PAD4 antibodies in patients with early and established RA. Results revealed that baseline anti-PAD4 antibodies are differentially associated with joint damage in early versus established RA, with an association with severe joint disease only apparent in those with established RA. Anti-PAD4 antibodies were modestly associated with lower #DAS28-CRP levels posttreatment in the early RA population; however, other disease metrics did not differ by anti-PAD4 antibody status. 🔗https://lnkd.in/dFGbZdMz
-
-
Early disease detection through lipidomics and polygenic scores --- We are excited to announce our latest co-authored publication, which explores the relationship between polygenic scores (PGSs) and lipid dysfunctions. Over 7000 individuals had their clinical lipid profiles and advanced lipidomics (179 lipid species) profiles analyzed. Nearly 700 significant associations between PGSs for 26 complex traits and 142 lipids were discovered. These associations offer insights into early lipid changes for diseases like type 2 diabetes, BMI, and venous thromboembolism. This study shows how PGSs can help detect lipid alterations in complex traits long before symptoms develop, helping us better understand disease mechanisms and design early prevention strategies. Read the full publication here: https://lnkd.in/eQYfkg9H #Genomics #Lipidomics #PrecisionMedicine #EarlyDiseaseDetection #lipotype #research #lipid #lipidomics #LipidMetabolism #lipidome
-
-
Some of the leading causes of death worldwide are pre-inflammatory or pre-symptomatic diseases such as cancer, chronic kidney disease (CKD), diabetes, hepatitis, Parkinson’s disease, Alzheimer’s disease, and hypertension. Read this article to learn how hydrogen therapy can be a promising protective agent against pre-symptomatic diseases based on published research and plant studies: https://lnkd.in/dkggN4QS #hydrogenmedicine #naturopathy #naturalmedicine #wellness
-
